Skip to main content

Table 2 Synoptic view of selected studies of ECT in cSCC

From: Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

First author, year publisheda Type of study No pts CR PR (%) OR (%) Follow-up (months) Drug
Belehradek M et al., Cancer 1993 [20] Phase I/II 8 57 15 73   
Allegretti JP et al., Laryngosc, 2001 [16] Phase I/II 14 51 36 87   
Burian M et al., Acta Otolaringol 2003 [21] Phase II 12 83 17 100   
Bloom DC et al., Eur J Sur Oncol 2005 [22] Phase II 54 25 32 57   
Matthiesen LW et al., 2011[23] Phase II 3      BLM i.t.&i.v.
Landstrom FJ et al., Acta Otolaryngol, 2011 [24]   15     24 BLM i.t.
Skarlatos I et al., 2011 [25] Prospective multicenter 14 9 (64.2) 4 (28.5) 13 (92.8) Nd BLM i.t.&i.v.
Gargiulo M et al., Ann Surg, 2012 [26] Retrospective 13 8 (61.5) 5 (38.4) 13 (100) 18 (range 4–48) BLM i.v.
Mevio N, et al., Tumori, 2012 [27] Prospective 13 7 (53.8) 4 (38.4) 11 (84.6) 8 (range 2–20) BLM i.v.
Benevento R et al., Surgery 2013 [28] Prospective 8 5 (50%) 3 (30%) 8 (100) 3 BLM i.v.
Solari N et al., J Surg Oncol, 2014[29] Prospective 5 Nd    6 BLM i.v.
Seccia V et al., Anticancer Res, 2014 [30] Prospective 8 2 (25) 5 (62) 7 (87) 9 (range 3–12) BLM i.v.
Campana LG et al., Br J Oral Maxillofac Surg, 2014 [31] Retrospective 24 6 (25) 6 (25) 12 (50) 14 (3–82) BLM i.t.&i.v.
Landstorm FJ et al., Acta Otolaryngol, 2015 [32]   4 4   4 24 BLM i.t.
Landstorm FJ et al., Acta Otolaryngol, 2015 [33] Prospective 18 Nd   (100) Median 58 months BLM i.t.
Domanico R et al., Drug Des Devel Ther, 2015 [34] Experimental 4 0 3 (75) 3 (75) 1 BLM i.v.
Campana LG et al., EJSO, 2016 [18] Prospective multicenter 35 14 (40.7%) 21 (60) 30 (85.2) 1–12 (evaluation at 2 months) BLM i.v.&i.t., CDDP i.t.
Rotunno R et al., G It Derm Venereol, 2015[35] Multicenter prospective not randomized phase II 25 13 (52) 7 (28) 20 (80) 13 BLM i.v.
Bertino G et al. Eur J Cancer, 2016 [36] Prospective multi center 50 26/47 (55) 11/47 (24) 37/47 (79) 2 BLM i.t.&i.v.
Di Monta G et al., current study Retrospective 22 22.7 59 81.7 34 (range 5–48) BLM i.v.
  1. aSome papers include also tumor of different histotype from SSCC